Prakt. lékáren. 2021; 17(2): e14-e18 | DOI: 10.36290/lek.2021.025

Hypertension treatment in stroke

Barbora Nussbaumerová
Centrum preventivní kardiologie, II. interní klinika LF a FN v Plzni

Stroke is the second most common cause of mortality worldwide and the third most common cause of disability. Arterial hypertension is the most prevalent risk factor for stroke. A precise management of arterial hypertension prevents the first episode of stroke as well as its recurrence. A rapid blood pressure lowering is not recommended in the acute phase of stroke. Blood pressure goals in chronic treatment are 140/90 mm Hg and lower, if tolerated. ACE inhibitors or angiotensin receptor blockers in combination with calcium channel blockers or indapamide are the preferred antihypertensive drugs.

Keywords: arterial hypertension, stroke, antihypertensive drugs.

Published: August 5, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nussbaumerová B. Hypertension treatment in stroke. Pharmacy for Practice. 2021;17(2):e14-18. doi: 10.36290/lek.2021.025.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Donkor ES. Stroke in the 21st Century: A Snapshot of the Burden, Epidemiology, and Quality of Life. Stroke Res Treat. 2018; 2018: 3238165. doi: 10.1155/2018/3238165. Go to original source... Go to PubMed...
    2. Kotseva K, De Backer G, De Bacquer D. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. European Journal of Preventive Cardiology 2019; 26(8). doi: https://doi.org/10.1177/2047487318825350. Go to original source... Go to PubMed...
    3. Lüscher TF. Epidemiology of cardiovascular disease: the new ESC Atlas and beyond European Heart Journal 2018; 39(7): 489-492. doi: https://doi.org/10.1093/eurheartj/ehy070 Go to original source... Go to PubMed...
    4. Samsa GP, Bian J, Lipscomb J, Matchar DB. Epidemiology of recurrent cerebral infarction: a medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke 1999; 30: 338-349. Go to original source... Go to PubMed...
    5. Feng W, Hendry HM, Adams RJ. Risk of recurrent stroke, myocardial infarction, or death in hospitalized stroke patients. Neurology 2010; 74(7). doi: https://doi.org/10.1212/WNL.0b013e3181cff776. Go to original source... Go to PubMed...
    6. Zanchetti A, Liu L, Mancia G, et al. Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. J Hypertens 2014; 32: 1741-1750. Go to original source... Go to PubMed...
    7. Cífková R, Wohlfahrt P, Krajčoviechová A, et al. Blood pressure control and risk profile in poststroke survivors: a comparison with the general population. J Hypertens. 2015; 33(10): 2107-2114. doi: 10.1097/HJH.0000000000000660. PMID: 26200884. Go to original source... Go to PubMed...
    8. Hong SK. Blood Pressure Management for Stroke Prevention and in Acute Stroke. J Stroke 2017; 19(2): 152-165. doi: 10.5853/jos.2017.00164. Go to original source... Go to PubMed...
    9. Kohok DD, Sico JJ, Bae F, et al. Post-stroke hypertension control and receipt of health care services among veterans. JCH 2018; 20(2): 382-387. doi: https://doi.org/10.1111/jch.13194 Go to original source... Go to PubMed...
    10. Ahmed N, Audebert H, Turc G, et al. Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11-13 November 2018. European Stroke Journal 2019; 4(4): 307-317. doi: https://doi.org/10.1177/2396987319863606. Go to original source... Go to PubMed...
    11. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal 2018; 39(33): 3021-3104. doi: https://doi.org/10.1093/eurheartj/ehy339. Go to original source... Go to PubMed...
    12. Williamson JD, Supiano MA, Applegate WB, et al. SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥ 75 years: a randomized clinical trial. JAMA 2016; 315: 2673-2682. Go to original source... Go to PubMed...
    13. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387: 957-967. Go to original source... Go to PubMed...
    14. Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015; 313: 603-615. Go to original source... Go to PubMed...
    15. PROGRESS Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358(9287): 1033-1041.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.